Silence Therapeutics plc
SLNCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.41 | 0.00 | -0.04 |
| FCF Yield | -5.28% | -9.63% | -7.69% | -6.83% |
| EV / EBITDA | -4.72 | -8.22 | -4.81 | 33.88 |
| Quality | ||||
| ROIC | -20.28% | -15.93% | -17.11% | -0.99% |
| Gross Margin | 59.75% | 62.05% | 61.97% | 93.40% |
| Cash Conversion Ratio | -0.22 | 0.80 | 0.43 | -1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.94% | -3.35% | 4.22% | 30.03% |
| Free Cash Flow Growth | 50.35% | -77.31% | 50.59% | -26.47% |
| Safety | ||||
| Net Debt / EBITDA | 3.15 | 1.86 | 3.27 | -16.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,324.42 | -7,100.23 | -20,682.00 | -107.61 |